ReviewNature reviews. Microbiology2016
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.
Review in Nature reviews. Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 358 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
358 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Roles of the gut microbiome in weight management.Nature reviews. Microbiology · 2023Pooled it
- Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria.NPJ biofilms and microbiomes · 2026Trial
- Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.Nature communications · 2022Trial
- Recent advances and clinical relevance of microbiome dynamics in health and disease.Gut microbes · 2026Review
- Article
- Role of the Gut Microbiome in Natural and Synthetic Drug Efficacy and Safety: A Narrative Review.Applied microbiology (Basel, Switzerland) · 2026Article
- Drug-microbiome-host interactions: antimicrobial effects of non-antibiotic compounds.Nature reviews. Gastroenterology & hepatology · 2026Review
- Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Gut Bacterial 20-Hydroxysteroid Dehydrogenases Modify Endogenous Glucocorticoids and Corticosteroid Drugs.Biochemistry · 2026Article
- Folic acid deficiency in cancer therapy: a review of chemotherapy-induced malabsorption and supportive care strategies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Recent antibiotic exposure and response to treatment of juvenile idiopathic arthritis: a retrospective cohort study.Arthritis research & therapy · 2026Article
- Article
- Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations.Pharmaceutics · 2026Review
- Developmental Programming of Drug Response: Microbiota as a Missing Dimension in Perinatal Drug Discovery.International journal of molecular sciences · 2026Review
- Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer.Nutrients · 2026Review
- Integration of human microbiota (SIHUMIx) and zebrafish models reveals microbiome-mediated host responses to azoxystrobin.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders.Antonie van Leeuwenhoek · 2026Review
- Multi-cohort Analysis Reveals Microbiome Signatures Associated with Drug Response in New-Onset Rheumatoid Arthritis.bioRxiv : the preprint server for biology · 2026Article
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
298 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although the importance of human genetic polymorphisms in therapeutic outcomes is well established, the role of our 'second genome' (the microbiome) has been largely overlooked. In this Review, we highlight recent studies that have shed light on the mechanisms that link the human gut microbiome to the efficacy and toxicity of xenobiotics, including drugs, dietary compounds and environmental toxins. Continued progress in this area could enable more precise tools for predicting patient responses and for the development of a new generation of therapeutics based on, or targeted at, the gut microbiome. Indeed, the admirable goal of precision medicine may require us to first understand the microbial pharmacists within.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.